Approximately 15% to 20% of patients visiting a medical practice are diagnosed with hypertriglyceridemia—frequently as an incidental finding (1). Given the increases in the prevalence of diabetes, metabolic syndrome, and obesity, the prevalence of hypertriglyceridemia is likely to increase too. The severity of hypertriglyceridemia (Table 1) varies widely, and to date no uniform classification of the condition has been established. To further complicate the matter, triglyceride (TG) levels can show intraindividual fluctuation. Most affected persons (80–90%) have moderately increased TG levels, i.e., between 150 mg/dL (1.7 mmol/L) and 400 mg/dL (4.6 mmol/L). In a small proportion of patients (approximately 15%), TG levels range between 400 mg/dL and 1000 mg/dL (4.6–11.4 mmol/L); occasionally, significantly higher levels are found (e1). In very rare cases, TG levels above 15 000 mg/dL (170 mmol/L) have been identified.

When interpreting TG concentrations, one should be aware that these threshold values apply to fasting TG levels. Since circulating TG levels after a meal can vary in both magnitude and duration, no postprandial thresholds have been established. TG levels typically peak 4 to 6 h after fat intake (e2).

Furthermore, there is currently no established “fat tolerance test”—by analogy with the glucose tolerance test—that would allow for standardized assessment of postprandial TG response. In metabolically healthy individuals, TG levels rarely increase above 400 mg/dL (4.6 mmol/L), even after a meal rich in fat (e2).

Hypertriglyceridemia is closely associated with the presence of obesity, metabolic syndrome, and diabetes mellitus. For instance, up to 50% of patients with type 2 diabetes have concomitant hypertriglyceridemia (6). Independent of this, there is frequently a
genetic predisposition, leading—in combination with lifestyle factors—to hypertriglyceridemia. This predisposition is usually polygenic and can include a wide range of serum TG. The spectrum ranges from a disposition resulting in hypertriglyceridemia only in the presence of considerable overweight and/or excessive alcohol consumption to very rare serious mutations (e.g., lipoprotein lipase and apolipoproteins A5, CII and CIII) that may lead to extremely severe hypertriglyceridemia in childhood, even in the absence of additional factors (familial chylomicronemia syndrome) (4, e3).

From a clinical perspective, hypertriglyceridemia is relevant in two respects:

First, patients with hypertriglyceridemia are at a higher risk of atherosclerosis and its late complications, with a causal, dose-dependent association for TG concentrations up to approximately 1000 mg/dL (11.4 mmol/L) (7). At even higher TG levels, there is probably no further increase in the already elevated risk of atherosclerosis. The increased risk reflects the fact that lipoproteins rich in TG contain apolipoprotein B (apoB); based on currently available evidence, all apoB-containing lipoproteins have an atherogenic effect (8). Since in the presence of TG levels >1000 mg/dL primarily the loading with TG increases, but not the number of lipoproteins, atherogenicity does not further increase with very high levels of TG (4). Simply on grounds of their size, lipoproteins very rich in TG are presumably not able to penetrate the subendothelial space to initiate the development of atherosclerosis.

The majority of patients with hypertriglyceridemia also have lower high-density lipoprotein (HDL)-cholesterol levels, and for a long time it was assumed that the increased atherosclerosis rate was caused by reduced HDL-cholesterol levels (e4). However, it is now clear that the increased cardiovascular risk is mediated by elevated levels of triglyceride-rich (apolipoprotein-B-containing) lipoproteins (4, 9). Since triglyceride-rich lipoproteins contain not only TG and apoB but also variable amounts of cholesterol (remnant cholesterol, also known as very low-density lipoprotein [VLDL]-cholesterol), the concentration of VLDL/remnant cholesterol is also associated with atherosclerosis (9).

Second, patients with very high TG levels (typically >1000 mg/dL; approximately 10 mmol/L) can develop acute pancreatitis (so-called chylomicronemia syndrome). Interestingly, epidemiological data have shown that the risk of pancreatitis is increased even at lower TG levels, although still very low in absolute terms: for instance, 2.7 pancreatitis events per 10 000 person-years were found for TG levels <1 mmol/L and 5.5 pancreatitis events per 10 000 person-years for TG levels of 2.0–3.0 mmol/L (hazard ratio [HR] = 1.8) (10). It is generally assumed that TG levels above approximately 1000 mg/dL (10 mmol/L) significantly increase the likelihood of pancreatitis (4). The risk is particularly high in patients with familial chylomicronemia syndrome (FCS).

**Diagnosis**

**Fasting versus non-fasting**

It was long assumed that fasting blood lipid levels should be measured. This approach reflects the fact that postprandial changes in TG levels are difficult to interpret. However, recent data have shown that postprandial lipoproteins also have an atherogenic effect and can be used for risk assessment (10–12). Furthermore, for a long time it had not been possible to measure LDL-cholesterol directly; instead, the Friedewald formula was used to estimate LDL-cholesterol levels (LDL-cholesterol = total cholesterol minus HDL-cholesterol minus triglycerides divided by 5 for mg/dL or by 2.2 for mmol/L) (13). A prerequisite for

---

**TABLE 1**

| Classification of hypertriglyceridemia based on fasting triglyceride levels |
| --- | --- | --- | --- |
| Designation               | Triglyceride levels | Clinical significance | Remarks |
| Normal finding            | <150 mg/dL (<1.7 mmol/L) | – Increased risk of cardiovascular events | The threshold level of 150 mg/dL is now accepted by all medical societies (2–5). |
| Moderate hypertriglyceridemia | 150–1000 mg/dL (1.7–11.4 mmol/L) | – Slightly increased risk of acute pancreatitis (dose-dependent) | Different medical societies define moderate hypertriglyceridemia differently:  
– Lower threshold: 150 mg/dL (175 mg/dL);  
– Upper threshold: between 500 mg/dL (5.6 mmol/L) (3) and 1000 mg/dL (11.4 mmol/L); 885 mg/dL (10 mmol/L) is also commonly reported (2, 3, 5). |
| Severe hypertriglyceridemia | >1000 mg/dL (>11.4 mmol/L) | – Significantly increased risk of acute pancreatitis (dose-dependent) | See remarks on "moderate hypertriglyceridemia" |

Deutsches Ärzteblatt International | Dtsch Arztebl Int 2019; 116: 825–32
the use of this equation is that blood is collected from fasting patients. Today, however, LDL-cholesterol is usually measured directly. In keeping with current recommendations, blood should be collected from fasting patients if one of the criteria listed in Box 1 is met (14). In primary care, measuring non-fasting lipid levels is considered adequate for initial screening. Irrespective of this, it should be taken into account that day-by-day fluctuation in TG levels is more pronounced than for LDL-cholesterol.

**Parameters to be tested**

Besides total cholesterol, TG, HDL-cholesterol, and LDL-cholesterol, the lipid profile should include the calculated non-HDL-cholesterol concentration (total cholesterol minus HDL-cholesterol). In addition to elevated TG, patients with hypertriglyceridemia typically have increased total cholesterol, decreased HDL-cholesterol, and normal to low LDL-cholesterol levels. The increase in total cholesterol is explained by the fact that all triglyceride-rich lipoproteins also contain cholesterol, which then raises the total cholesterol level. The parameter non-HDL-cholesterol specifies the amount of cholesterol associated with triglyceride-rich lipoproteins (VLDL-cholesterol or remnant cholesterol). The advantage of determining non-HDL-cholesterol is that the concentration of all atherogenic lipoproteins can be estimated by measuring one single parameter. The level of non-HDL-cholesterol is more closely correlated with adverse cardiovascular events than that of TG as it also includes LDL-cholesterol. Furthermore, atherogenicity increases with rising TG levels only if more lipoproteins are present, not when existing lipoproteins are loaded with additional TG (e5). Here, the concentration of remnant cholesterol is—like the concentration of apolipoprotein B—superior to TG concentration as a marker for the amount of abnormal lipoproteins (9).

Therefore, the current European guidelines for the management of dyslipidemias recommend non-HDL-cholesterol as a secondary target for lipid lowering (Table 2) (5). In patients without hypertriglyceridemia, the non-HDL-cholesterol level exceeds the LDL-cholesterol level by no more than 30 mg/dL (0.8 mmol/L).

Additional investigations (apolipoprotein B concentration, apolipoprotein E phenotype, genetic testing) are reserved for special situations (suspected FCS; evaluation of new treatment approaches), since in general their results have no impact on clinical decision making. Whenever a patient is diagnosed with hypertriglyceridemia, the first step is to rule out secondary causes (Box 2). However, for patients to develop overt hypertriglyceridemia as the result of such secondary causes, an underlying genetic predisposition is usually required.

**Management**

In the management of hypertriglyceridemia, therapeutic interventions (Table 3) aim at reducing the risk of cardiovascular events and pancreatitis. Therefore, the European medical societies have specified target levels for lipids according to the overall risk (Table 2).

**BOX 1**

**Situations in which fasting triglyceride levels should be determined (14)**

- Non-fasting triglyceride levels >440 mg/dL (5 mmol/L)
- Known hypertriglyceridemia
- Following hypertriglyceridemia-associated pancreatitis
- Before starting medications that may cause hypertriglyceridemia
- Whenever other tests require fasting blood collection (e.g., determination of blood glucose or drug levels)

---

**TABLE 2**

<table>
<thead>
<tr>
<th>Cardiovascular risk</th>
<th>Primary target level</th>
<th>Grade of recommendation/level of evidence</th>
<th>Secondary targets</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LDL-cholesterol</td>
<td>Non-HDL-cholesterol</td>
<td>apoB</td>
</tr>
<tr>
<td></td>
<td>mg/dL</td>
<td>mmol/L</td>
<td>mg/dL</td>
</tr>
<tr>
<td>Low</td>
<td>&lt;116</td>
<td>&lt;3.0</td>
<td>Iib/A</td>
</tr>
<tr>
<td>Moderate</td>
<td>&lt;100</td>
<td>&lt;2.6</td>
<td>Iia/A</td>
</tr>
<tr>
<td>High</td>
<td>&lt;90</td>
<td>&lt;1.8</td>
<td>I/A</td>
</tr>
<tr>
<td>Very high</td>
<td>&lt;55</td>
<td>&lt;1.4</td>
<td>I/A</td>
</tr>
</tbody>
</table>

*Estimation of the cardiovascular risk based on clinical parameters and the European Society of Cardiology risk score (10-year risk of fatal cardiovascular disease); for example, “very high risk” with evidence of atherosclerotic disease or score >20% or “high risk” with diabetes without evidence of end-organ damage.

*These targets may be considered.
For patients with hypertriglyceridemia, primarily the same standard target LDL-cholesterol levels apply as for persons without hypertriglyceridemia. Non-HDL-cholesterol and apoB represent secondary targets of lipid lowering, because the related evidence from randomized trials is weaker than that available for LDL-cholesterol. This reflects the fact that the design and statistical analysis of most large trials of lipid-lowering regimens focused on LDL-cholesterol.

The recommendations of the UK National Institute for Health and Care Excellence (NICE) follow a similar line of reasoning: For patients with hypertriglyceridemia, NICE recommends optimization of the cardiovascular risk profile on the basis of non-HDL-cholesterol, but does not mention concrete target levels (15). Likewise, the German College of General Practitioners and Family Physicians (DEGAM, Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin) points out that the cardiovascular risk is increased in patients with both hypertriglyceridemia and combined hyperlipoproteinemia (16).

### TABLE 3

**Interventions to treat hypertriglyceridemia**

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Lowering of TG</th>
<th>Remarks</th>
<th>Evidence level</th>
</tr>
</thead>
</table>
| Lifestyle modification        | Variable; up to 70% | – Alcohol abstinence and reduced intake of rapidly metabolizable carbohydrates have the greatest effect (e6, e7)  
– Increasing physical activity; the goal is >2.5 h (better 5 h) of aerobic exercise of moderate intensity spread over the week (e6)  
– Very variable effect: depends on the baseline condition and the underlying predisposition  
– Nutritional counseling should be offered to all patients | A              |
| Weight loss                   | Variable; up to 70% | – Particularly effective in patients with abdominal obesity or with other factors related to metabolic syndrome (e6)  
– Variable effect: in some patients very pronounced lowering of TG levels after losing only a few kilograms of weight; in other patients minor effect despite significant weight loss | A              |
| Blood glucose control         | Variable; up to 70% | – In type 2 diabetes mellitus: in many cases significant improvement, but usually no return to normal blood glucose levels; largely independent of the anti-diabetic agent used  
– In type 1 diabetes mellitus: hypertriglyceridemia usually only if blood glucose is uncontrolled; return to normal after control has been achieved | A              |
| Administration of fibrates    | 30–50%          | – As monotherapy or in combination with non-statin (old studies): minor positive effect on cardiovascular endpoints (25, e13)  
– In combination with statins: no positive effects in endpoint studies, but potential benefits in subgroups (26, 27)  
– Consider use in patients with very high cardiovascular risk and persistent hypertriglyceridemia (5)  
– Try fibrates in patients with severe hypertriglyceridemia | A              |
| Administration of omega-3 fatty acids | 30–50% | – Low-dose (1–2 g daily) omega-3 fatty acids show no clinical benefits (31)  
– High-dose (3–4 g daily) omega-3 fatty acids should be considered in patients with high cardiovascular risk and persistent hypertriglyceridemia (4)  
– Try omega-3 fatty acids in patients with severe hypertriglyceridemia  
– In one study (REDUCE-IT), treatment with eicosapentaenoic acid ethyl ester at a dose of 4 g daily showed significant clinical benefits in high-risk patients with statin therapy; the mechanism of action is unclear (32) | A              |
| Administration of MCT fats    | Variable        | – As a replacement for other fats; hardly any effect on fasting lipids, but no postprandial TG increase; in the medium term, in most patients improved fasting TG levels (because postprandial lipoproteins can also be detected in fasting blood specimens of patients with severe hypertriglyceridemia)  
– Consider use in patients with low uncontrolled TG levels (4) | B              |
| Administration of statins     | 10–20%          | – Used to reduce cardiovascular risk depending on overall risk and LDL-cholesterol, minor direct effect on TG (21) | A              |
| Administration of ezetimibe   | 5–10%           | – Used to reduce cardiovascular risk in addition to statins depending on overall risk and LDL-cholesterol; no direct effect on TG (e10) | B              |
| Administration of PCSK9 inhibitors | 10–20% | – Used to reduce cardiovascular risk in addition to maximum oral treatments depending on overall risk and LDL-cholesterol, minor direct effect on TG (e11, e12) | A              |
| Administration of bile acid sequestrants | Increase | – Contraindicated; bile acid sequestrants can increase TG levels in patients with hypertriglyceridemia | B              |

**Notes:**

- LDL, Low-density lipoprotein; MCT, medium-chain triglycerides; PCSK9, proprotein convertase subtilisin/kexin type 9; TG, triglyceride(s)
levels is advisable. However, there are differences in the approach to lipid reduction: The European and now also the US medical societies define precise target LDL levels, whereas other medical societies do not state specific targets. We support the use of target levels as these facilitate the communication with patients and with other healthcare providers, making this the best approach to ensure that patients are treated according to their respective risk. Another difference concerns age limits. While the US recommendations focus on the age group from 40 to 75 years (for which there is evidence from studies), the European guidelines do not limit their recommendations to this age group and extrapolate the evidence for those age groups for which no or only limited data are available.

**Lifestyle modifications**

Lifestyle modifications are of paramount importance when treating patients with hypertriglyceridemia (e6–e9). The key measures are to avoid alcohol and to significantly reduce the intake of rapidly metabolizable carbohydrates, especially drinks containing sugar (17). In addition, the intake of animal fats should be restricted. However, there are as yet no cardiovascular endpoint studies demonstrating the benefits of lifestyle modifications. Given the central role of lifestyle changes, patients should be offered the opportunity to receive nutritional counseling. Equally important is an increase in physical activity to a level of 2.5 to 5 h per week of moderate-intensity aerobic exercise (18).

In overweight patients, the goal is to bring about weight loss and in patients with diabetes mellitus, to achieve good blood sugar control. In addition, it is important to take into account that the response to lifestyle modifications varies considerably between individuals.

TG-lowering pharmacotherapy should be started only after lifestyle modifications have been implemented and control of diabetes has been achieved. Overall, in our experience, only a small proportion of patients with hypertriglyceridemia (approximately 10%) require specific drug treatment to lower TG levels.

**Drug treatment of hypertriglyceridemia**

The primary goal of pharmacotherapy is to reduce the incidence of cardiovascular events. Since studies have yielded unequivocal evidence that this reduction is achieved by lowering LDL-cholesterol levels, the first step in the management of patients with hypertriglyceridemia is to attempt to achieve the target LDL-cholesterol level (19). For this purpose, the strategies available for lowering LDL-cholesterol levels (lifestyle modifications, statins, ezetimibe, PCSK9 inhibitors) should be used, taking into account the overall risk (20, 21, e10–e12). While the above-mentioned medications do not lower TG levels, they are indicated for the reduction of the cardiovascular risk. Bile acid sequestrants should not be used, as they can amplify any existing hypertriglyceridemia; moreover, there is no evidence that cardiovascular events are reduced by a combination of bile acid sequestrants and statins (22).

Once the target LDL-cholesterol level has been achieved, and taking into account the overall risk, the decision has to be made whether a specific treatment for hypertriglyceridemia is required to achieve the non-HDL-cholesterol target (secondary target). This decision is primarily based on the extent of hypertriglyceridemia and the absolute risk. Drug treatment should always be considered if the TG level is above 400 mg/dL (4.7 mmol/L), on the assumption that much higher levels (at times >1000 mg/dL, 11.4 mmol/L) will be reached intermittently (for example, after a meal or with alcohol consumption).

**Fibrates**

Fibrates can variably reduce TG levels by 20% to 70% (23, 24). Some studies from the “pre-statin era” showed that fibrate treatment also results in a reduction of the cardiovascular risk (25, e13). In the Helsinki Heart Study of 4081 men, gemfibrozil treatment led to a relative risk reduction for cardiovascular endpoints by 37% (absolute risk reduction: 14.1%) and the VA-HIT study of 2531 men found a relative risk reduction of 22% (absolute risk reduction: 4.4%) in those treated with gemfibrozil (25, e13). By contrast, studies evaluating fibrates in combination with statins found no additional benefit (26). A Cochrane analysis also concluded that fibrates should be used very restrictively (24). Because of its very high potential for interactions

<table>
<thead>
<tr>
<th>Secondary causes of hypertriglyceridemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Overweight/obesity</td>
</tr>
<tr>
<td>- Metabolic syndrome</td>
</tr>
<tr>
<td>- Diabetes mellitus</td>
</tr>
<tr>
<td>- Increased alcohol consumption</td>
</tr>
<tr>
<td>- Excessive calorie intake (as fat or rapidly metabolizable carbohydrates)</td>
</tr>
<tr>
<td>- Hypothyroidism</td>
</tr>
<tr>
<td>- Kidney disorders (especially nephrotic syndrome)</td>
</tr>
<tr>
<td>- Paraproteinemia</td>
</tr>
<tr>
<td>- Systemic lupus erythematosus</td>
</tr>
<tr>
<td>- Anorexia nervosa</td>
</tr>
<tr>
<td>- Glycogenoses</td>
</tr>
<tr>
<td>- Sepsis</td>
</tr>
<tr>
<td>- Pregnancy</td>
</tr>
<tr>
<td>- Medications: steroids, estrogens, anabolics, tamoxifen, thiazides, non-cardioselective beta blockers, cyclophosphamide, cyclosporine, protease inhibitors, bile acid sequestrants, clozapine, atypical antipsychotics, antidepressants, etc.</td>
</tr>
</tbody>
</table>

---

**BOX 2**

**Secondary causes of hypertriglyceridemia**

- Overweight/obesity
- Metabolic syndrome
- Diabetes mellitus
- Increased alcohol consumption
- Excessive calorie intake (as fat or rapidly metabolizable carbohydrates)
- Hypothyroidism
- Kidney disorders (especially nephrotic syndrome)
- Paraproteinemia
- Systemic lupus erythematosus
- Anorexia nervosa
- Glycogenoses
- Sepsis
- Pregnancy
- Medications: steroids, estrogens, anabolics, tamoxifen, thiazides, non-cardioselective beta blockers, cyclophosphamide, cyclosporine, protease inhibitors, bile acid sequestrants, clozapine, atypical antipsychotics, antidepressants, etc.
Possible treatment algorithm for patients with HTG.

It should be taken into account that the goals "cardiovascular risk reduction" and "pancreatitis prevention" cannot be clearly separated. The overall risk is based on the cardiovascular risk and can be assessed using the ESC risk score (5). Box 2 provides an overview of secondary causes.

<table>
<thead>
<tr>
<th>Triglycerides &lt;10 mmol/L (885 mg/dL)*3</th>
<th>Triglycerides ≥ 10 mmol/L (885 mg/dL)*3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triglycerides elevated</td>
<td></td>
</tr>
<tr>
<td>Non-HDL-cholesterol goal not achieved</td>
<td></td>
</tr>
</tbody>
</table>

Primary goal: Cardiovascular risk reduction

- Define and achieve LDL-cholesterol goal
- Define non-HDL-cholesterol goal
- Identify and treat secondary causes of HTG
- Implement lifestyle modifications

Further lowering of triglycerides required:

- Intensify lifestyle modifications
- Consider use of fibrates and/or omega-3 FA
- Consider administration of MCT fats
- Consult lipidologist

Triglycerides ≥ 10 mmol/L (885 mg/dL)*3

Consider experimental (novel) approaches

with other medications, especially statins, gemfibrozil should be used only in exceptional cases and then always by pharmaceutically experienced physicians.

Nevertheless, in patients with hypertriglyceridemia and a very high risk (for example progression of atherosclerotic disease despite achieving target LDL levels) the use of fibrates may be considered, because analyses in subgroups of the above-mentioned studies hinted at potential benefits in this constellation (24, 27). Special mention should be made of ongoing studies evaluating whether patients with high risk and elevated TG levels may benefit from fibrates in combination with statins (28).

In patients with extremely high TG levels (>1000 mg/dL, approximately 10 mmol/L; pancreatitis prevention), it should be established on an individual basis whether fibrates are effective. After about 4 to 6 weeks, during which lifestyle modifications are rigorously maintained, patients should be reevaluated. If no clinically relevant effect (reduction >30%) is found during reevaluation, the medication should be discontinued. The available evidence does not indicate that fibrates can reduce the risk of pancreatitis.

### Omega-3 fatty acids

High doses of omega-3 fatty acids (>1.5–2 g icosapent ethyl plus 1.2–1.5 g docosahexaenyl ethyl daily) have a triglyceride-lowering effect (about 25–30%). However, the evidence from studies evaluating the use of low-dose omega-3 fatty acids (1 g daily) to prevent cardiovascular events is neutral (29–31). Thus, there is no reason to initiate treatment with low doses of omega-3 fatty acids.

By contrast, the recently published REDUCE-IT study has shown that with a considerably higher dose (4 g daily) of a specific omega-3 fatty acid (icosapent ethyl = eicosapentaenoic acid [EPA] ethyl ester) the incidence of cardiovascular events was greatly reduced (32). In this study of 8179 patients (high risk, receiving statin treatment), relative risk reduction by 25% and absolute risk reduction by 4.8% were achieved (number needed to treat [NNT] = 21 over a period of 4.9 years). It remains unclear by what mechanism this positive effect was brought about and whether the difference between the results of this study and the results of other analyses on omega-3 fatty acids was due to the choice of a different patient population, the administration of a higher dose, the use of potentially harmful mineral oil as a comparator, or the use of a specific omega-3 fatty acid. It is also striking that patients benefited from the treatment regardless of their baseline TG levels. In this respect, it is worth mentioning that another study evaluating a higher dose of omega-3 fatty acids is currently being conducted; after completion of that study (expected for 2021), it will be possible to define more closely which patient population actually benefits from such an intervention (33).

As for fibrates, treatment with omega-3 fatty acids should be tried in patients with excessively high TG levels treatment with this substances in the attempt to determine which strategies, including combinations, lead to the lowest TG levels.

### New treatment approaches

For patients with very rare, severe, hereditary forms of hypertriglyceridemia (e.g., FCS caused by a lipoprotein lipase defect), novel treatments are in clinical development.
Key messages

- Hypertriglyceridemia can be divided into moderate (TG levels from 150 mg/dL to about 1000 mg/dL) and severe (TG levels >1000 mg/dL) forms.
- In patients with moderate hypertriglyceridemia, the focus is on the increased cardiovascular risk, severe hypertriglyceridemia, on the increased risk of pancreatitis.
- Lifestyle factors and comorbidities (diabetes mellitus) contribute to the development of hypertriglyceridemia in patients with an underlying genetic predisposition.
- Lifestyle modifications (avoiding alcohol; reducing rapidly metabolizable carbohydrates; weight loss; physical activity) are the mainstays of treatment.
- The use of medications depends on an individual's risks for cardiovascular disease and pancreatitis.

Deutsches Ärzteblatt International | Dtsch Arztebl Int 2019; 116: 825–32

Manuscript received on 6 March 2019, revised version accepted on 23 September 2019
Translated from the original German by Ralf Thoene, MD.

References


Corresponding author
Prof. Dr. Klaus G. Parhofer
Medizinische Klinik IV – Großhadern
Klinikum der Universität München
Marchioninstr. 15
81377 München, Germany
Klaus.parhofer@med.uni-muenchen.de

Cite this as:

Supplementary material
For eReferences please refer to:
www.aerzteblatt-international.de/ref4919

Deutsches Ärzteblatt International | Dtsch Arztebl Int 2019; 116: 825–32

832
The Diagnosis and Treatment of Hypertriglyceridemia

by Klaus G. Parhofer and Ulrich Laufs


eReferences